Amphora Discovery

Amphora Discovery was a biotechnology company specializing in high-throughput drug discovery and chemical genomics. Utilizing advanced microfluidic technology licensed from Caliper Life Sciences, the company focused on identifying small molecule leads across major drug target classes such as kinases and GPCRs. Amphora's business model centered on building a comprehensive database of compound-target interactions to accelerate the drug development process for its pharmaceutical partners. The company integrated automated screening with advanced informatics to map the interactions between small molecules and the human proteome. Their platform allowed for the rapid identification of potent and selective inhibitors, which were then progressed through partnerships with major pharmaceutical firms. In 2006, the company's assets and discovery operations were acquired by Evotec to bolster its drug discovery services and internal pipeline.